Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer and liver cancer. Provectus investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for psoriasis. In addition, Provectus has begun a Phase 3 trial as a therapy for metastatic melanoma. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
The red synthetic dye Rose Bengal is shown in a bottle at Provectus Pharmaceuticals, Inc.
CURRENT PVCT PIPELINE (as of May 23, 2017)
Charts and Technical:
PVCT 6 months chart:
PVCT News and Analysis:
PVCT News Blog with the latest news and analysis:
CONNECTING THE DOTS - CURRENT NEWS PAGE
CONNECTING THE DOTS - BLOG PAGE
PVCT News at OTC
CLINICAL TRIALS Updates and Info:
|PVCT News: Current Report Filing (8-k)||06/23/2022 09:14:47 AM|
|PVCT News: Additional Proxy Soliciting Materials (definitive) (defa14a)||06/22/2022 09:04:28 AM|
|PVCT News: Current Report Filing (8-k)||06/22/2022 09:01:57 AM|
|PVCT News: Additional Proxy Soliciting Materials (definitive) (defa14a)||05/26/2022 01:28:15 PM|
|PVCT News: Quarterly Report (10-q)||05/12/2022 01:49:15 PM|